3-(3,5-Difluoro-4-methoxyphenyl)propanol | 105219-45-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(3,5-Difluoro-4-methoxyphenyl)propanol
• 英文别名: 3-(3,5-difluoro-4-methoxyphenyl)propan-1-ol
• CAS: 105219-45-2
• 化学式: C₁₀H₁₂F₂O₂
• 分子量: 202.201
• InChiKey: SGAMTIXKSFXLTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3,5-Difluoro-4-methoxyphenyl)propanol 、 对甲苯磺酰氯 以15.6 g (95%)的产率得到3-(3,5-Difluoro-4-methoxyphenyl)propyl azide
  参考文献：
  名称：

  Dopamine-.beta.-hydroxylase inhibitors and use thereof

  摘要：

  这项发明的化合物是1-苯基烷基-2-巯基四唑化合物，它们是多巴胺-β-羟化酶抑制剂。

  公开号：

  US04707488A1
• 作为产物：
  描述：

  3-(3,5-二氟-4-甲氧基苯基)丙酸 以14.6 g (99%)的产率得到3-(3,5-Difluoro-4-methoxyphenyl)propanol
  参考文献：
  名称：

  Dopamine-.beta.-hydroxylase inhibitors and use thereof

  摘要：

  这项发明的化合物是1-苯基烷基-2-巯基四唑化合物，它们是多巴胺-β-羟化酶抑制剂。

  公开号：

  US04707488A1

文献信息

• 4-Aralkyl-5-substituted-1,2,4-triazole-5-thiols
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0323737A1

  公开（公告）日：1989-07-12

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are described in which, n is 0 to 5; X¹ to X⁵ are any accessible combination of hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, cyano, nitro, SONH₂, SO₂NH₂, SO₂CH₃, SO₂CH₂F, SO₂CHF₂, SO₂CF₃, CF₃, CHO, OH, CH₂OH, CO₂H, or CO₂CpH2p+1 wherein p is 1 to 4; R¹ is phenyl substituted by X¹ to X⁵, C₁₋₄alkyl, C₃₋₆cycloalkyl, or an arylC₁₋₄alkyl group substituted by X¹ to X⁵; R² is hydrogen, C₁₋₄alkyl or (CH₂)m-CO₂R³; m is 0 to 5; and R³ is H or C₁₋₄alkyl. These compounds are dopamine-β-hydroxylase inhibitors. Pharmaceutical compositions are described as are methods of use. Processes for the preparation of these compounds are described.

  描述了式（I）的化合物及其药学上可接受的盐，其中，n为0至5；X¹至X⁵为氢、卤素、C₁₋₆烷基、C₁₋₆烷氧基、氰基、硝基、SONH₂、SO₂NH₂、SO₂CH₃、SO₂CH₂F、SO₂CHF₂、SO₂CF₃、CF₃、CHO、OH、CH₂OH、CO₂H或CO₂CpH2p+1的任意可访问组合，其中p为1至4；R¹为被X¹至X⁵取代的苯基、C₁₋₄烷基、C₃₋₆环烷基或被X¹至X⁵取代的芳基C₁₋₄烷基基团；R²为氢、C₁₋₄烷基或（CH₂）m-CO₂R³；m为0至5；R³为H或C₁₋₄烷基。这些化合物是多巴胺-β-羟基化酶抑制剂。描述了药物组合物以及使用方法。描述了这些化合物的制备过程。
• Dopamine-beta-hydroxylase inhibitors
  申请人：SmithKline Beckman Corporation

  公开号：US04810811A1

  公开（公告）日：1989-03-07

  The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-.beta.-hydroxylase inhibitors.

  本发明的化合物是1-苯基烷基-2-巯基四唑化合物，是多巴胺-β-羟化酶抑制剂。
• 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES
  申请人：Aissaoui Hamed

  公开号：US20100093740A1

  公开（公告）日：2010-04-15

  The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH 2 or O; R 1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R 2 represents (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 2-4 )alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR 5 R 6 or cyclopropyl; R 3 represents (C 1-4 )alkyl, (C 1-4 )alkoxy-methyl or halogen; R 4 represents (C 1-4 )alkyl; R 5 represents hydrogen or (C 1-4 )alkyl; and R 6 represents hydrogen or (C 1-4 )alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

  本发明涉及公式（I）的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物，其中X代表CH2或O; R1代表苯基，该基团独立地单取代、双取代或三取代，其中取代基独立地选自由（C1-4）烷基，（C1-4）烷氧基，卤素，氰基，三氟甲氧基和三氟甲基的群组; R2代表（C1-4）烷基，（C1-4）烷氧基，（C2-4）烯基，卤素，氰基，羟甲基，三氟甲基，C（O）NR5R6或环丙基; R3代表（C1-4）烷基，（C1-4）烷氧甲基或卤素; R4代表（C1-4）烷基; R5代表氢或（C1-4）烷基; R6代表氢或（C1-4）烷基。本发明还涉及这种化合物的药学上可接受的盐;以及将这种化合物用作药物的用途;特别是作为促进睡眠激素受体拮抗剂。
• Dopamine-bêta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0191621A2

  公开（公告）日：1986-08-20

  Compounds of structure (II) in which R is hydrogen or C1-4 alkyl; n is 1 to 5; and R2 to R6 are the same or different and are each hydrogen, halogen, hydroxy, CI-4 alkyl, CN, N02, S02NH2, C02H, CONH2, CHO, CH20H, CF3, C1-4alkoxy, SO2C1-4 alkoxy, SO2C1-4fluoroalkyl or CO2C1-4 alkyl, and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy as dopamine-β-hydroxylase inhibitors.

  结构(II)的化合物，其中R为氢或C1-4烷基；n为1至5；R2至R6相同或不同，且各自为氢、卤素、羟基、CI-4烷基、CN、N02、S02NH2、C02H、CONH2、CHO、CH20H、CF3、C1-4烷氧基、SO2C1-4烷氧基、SO2C1-4氟烷基或CO2C1-4烷基，以及它们的药学上可接受的盐、它们的制备工艺、含有它们的药物组合物和它们作为多巴胺-β-羟化酶抑制剂在治疗中的用途。
• KALSER, CARL;KRUSE, LAWRENCE I.
  作者：KALSER, CARL、KRUSE, LAWRENCE I.

  DOI：——

  日期：——